Fox Run Management L.L.C. Takes $981,000 Position in Novo Nordisk A/S $NVO

Fox Run Management L.L.C. acquired a new stake in Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 17,673 shares of the company’s stock, valued at approximately $981,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. True Wealth Design LLC lifted its position in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the period. Guerra Advisors Inc purchased a new position in Novo Nordisk A/S during the third quarter valued at approximately $25,000. Strengthening Families & Communities LLC bought a new position in Novo Nordisk A/S in the third quarter worth approximately $30,000. NewSquare Capital LLC lifted its holdings in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares during the period. Finally, Steigerwald Gordon & Koch Inc. bought a new stake in Novo Nordisk A/S during the 3rd quarter valued at $39,000. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on NVO shares. Morgan Stanley reissued an “underweight” rating and issued a $42.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a report on Thursday, January 22nd. TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, February 5th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday. Six investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $56.07.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $37.62 on Friday. The company has a 50 day moving average price of $52.96 and a 200 day moving average price of $52.93. The firm has a market capitalization of $167.97 billion, a P/E ratio of 10.84 and a beta of 0.67. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 52 week low of $37.31 and a 52 week high of $91.90.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 23.63%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Positive Phase‑2 China results for a triple‑agonist (UBT251) that produced ~20% body‑weight loss, bolstering Novo’s obesity pipeline and collaboration footprint in Greater China. Novo Nordisk’s China Obesity Drug Cuts Nearly One-Fifth Of Body Weight
• Positive Sentiment: Novo signed a strategic deal with Vivtex to develop next‑generation oral obesity/diabetes medicines (deal valued up to ~$2.1bn), which could extend market reach beyond injectables if the oral delivery works at scale. Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs
• Neutral Sentiment: Short interest fell meaningfully in February (roughly a 15% drop), reducing one source of selling pressure and lowering the days‑to‑cover — a technical datapoint worth monitoring for volatility changes.
• Negative Sentiment: Multiple analyst downgrades and coverage cuts have pressured the stock, with recent notes and headlines pointing to reduced ratings and target cuts amid pipeline and competitive concerns. Novo Nordisk A/S (NYSE:NVO) Stock Rating Lowered by Kepler Capital Markets
• Negative Sentiment: Shareholder litigation inquiries and class‑action investigations have been announced (Pomerantz, Schall Law Firm), creating legal overhang and potential costs/distraction for management. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
• Negative Sentiment: Pricing pressure and a reported halving of Wegovy prices have heightened margin and competitive concerns, feeding the narrative of a structural challenge in the obesity franchise. Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.